BrainsWay Reports Q4 Earnings: Revenue Beat, Guidance Below Estimates

BrainsWay Ltd. (NASDAQ:BWAY) reported fourth-quarter financial results on Wednesday ahead of the market open. Here’s a look at the key details from the report.

• BrainsWay stock is trending lower. Why is BWAY stock falling?

Q4 Financial Results

BrainsWay reported earnings per share of 4 cents, inline with the consensus estimate. In addition, it reported revenue of $14.54 million, beating the consensus estimate of $14.01 million and representing a 27% year-over-year increase.

The company shipped a net total of 95 Deep TMS systems during the fourth quarter, a 27% increase from the same period last year, bringing the total installed base to approximately 1,700 systems.

BrainsWay said remaining performance obligations increased 43% to approximately $70 million.

"Demand for Deep TMS continues to accelerate, supported by expanding customer adoption, additional regulatory clearances, and growing reimbursement coverage," said CEO Hadar Levy.

The U.S. Food and Drug Administration (FDA) granted label expansion for Deep TMS system, making the treatment available as an adjunct therapy for adolescents aged 15 to 21 years suffering from major depressive disorder (MDD).

Looking ahead, the company expects fiscal-year revenue of $51.00 million to $52.00 million, versus the consensus estimate of $64.98 million.

BrainsWay Shares Edge Lower

BWAY Price Action: At the time of publication, BrainsWay shares are trading 0.39% lower at $12.66, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.